Can Intravenous Cotrimoxazole Cause Lactic Acidosis?
Yes, intravenous cotrimoxazole can cause lactic acidosis, primarily through propylene glycol toxicity contained in the IV formulation, and this is a recognized adverse effect that requires immediate discontinuation of the drug when suspected.
Mechanism and Evidence
The FDA drug label explicitly warns that IV cotrimoxazole contains propylene glycol (38.6% v/v) as a solvent, which is metabolized in the liver to lactic acid 1. When administered at high doses—particularly for Pneumocystis jirovecii pneumonia treatment—this can lead to hyperosmolarity with anion gap metabolic acidosis, including lactic acidosis 1.
Clinical Presentation
The lactic acidosis typically develops early in treatment, between days 3-7 of IV cotrimoxazole administration 2. Key features include:
- Metabolic acidosis with elevated anion gap (>16 mEq/L)
- Elevated lactate levels (can reach >12 mmol/L)
- Associated gastrointestinal symptoms: nausea, vomiting, epigastric pain, abdominal distention 2, 3
- Normal hemodynamic status: patients may not be hypotensive or severely hypoxic 4
- Normal renal and liver function in many cases 4
Incidence and Risk Factors
While the exact incidence is not well-defined, case series show this occurs in a substantial proportion of patients receiving high-dose IV cotrimoxazole. One retrospective/prospective study found metabolic acidosis developed in 67% of patients treated for PCP 2.
High-risk patients include those:
- Receiving high doses for PCP treatment (15-20 mg/kg/day of trimethoprim component)
- With concurrent use of other propylene glycol-containing medications
- With renal dysfunction (though can occur with normal renal function) 1
- Receiving prolonged therapy
Management Algorithm
1. Immediate Actions When Lactic Acidosis Suspected
- Discontinue IV cotrimoxazole immediately 1, 4
- Measure arterial blood gas, lactate level, anion gap, and electrolytes
- Monitor for acid-base disturbances 1
2. Supportive Care
- Conservative management is usually sufficient: The acidosis typically resolves within 24 hours of drug cessation 4, 2
- Intravenous bicarbonate may be administered if severe (pH <7.2) 2, 3
- Maintain adequate hydration
- In severe cases unresponsive to conservative measures, consider renal replacement therapy 5
3. Alternative Therapy
- Switch to alternative agents for PCP treatment (e.g., pentamidine, atovaquone, or clindamycin-primaquine)
- Do NOT use oral cotrimoxazole as substitute if propylene glycol toxicity suspected, as the mechanism is formulation-specific
Critical Pitfalls to Avoid
Do not attribute lactic acidosis solely to sepsis or hypoperfusion in hemodynamically stable patients receiving IV cotrimoxazole—consider drug-induced etiology 4, 3
Do not continue IV cotrimoxazole while investigating other causes of lactic acidosis—the risk-benefit strongly favors immediate discontinuation given rapid reversibility 4
Monitor total propylene glycol load from all IV medications, not just cotrimoxazole 1
Distinguish from type 4 renal tubular acidosis: Cotrimoxazole can also cause hyperkalemic non-anion gap metabolic acidosis through a different mechanism (trimethoprim-induced potassium retention), which presents differently 6
Special Populations
HIV/AIDS patients receiving high-dose IV cotrimoxazole for PCP are particularly vulnerable and may develop this complication despite favorable clinical response to therapy 3. The FDA label specifically notes that AIDS patients may not tolerate cotrimoxazole in the same manner as non-AIDS patients 1.
Monitoring recommendation: Check lactate levels and acid-base status at baseline and between days 3-7 of high-dose IV cotrimoxazole therapy, particularly in patients receiving treatment for PCP 2.